Encompass Health Corporation

$104.01 ▲ 4.18%
2026-06-06 07:45:01

Explore Encompass Health Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$10.32 B
Current Price
$104.01
52W High / Low
$127.99 / $92.77
Stock P/E
16.94
Book Value
$24.38
Dividend Yield
0.76%
ROCE
16.84%
ROE
25.35%
Face Value
EPS
$5.99
Exp Qtr EPS
Sector
Healthcare

EHC — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Healthy return on equity.
  • Efficient use of capital employed.
  • Strong operating margin profile.
  • Valuation is not stretched on P/E basis.
  • Meaningful dividend yield is available.

Cons

  • Some data points may be missing or delayed because the source is not an official exchange feed.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Tenet Healthcare Corporation $162.06 8.23 $14.01 B 13.64% 40.55% $247.21 / $146.6 $48.53
2. DaVita Inc. $192.16 15.81 $12.36 B 14.02% 181.22% $202.69 / $101 $1.5
3. The Ensign Group, Inc. $170.3 26.94 $9.79 B 0.16% 9.31% 16.64% $218 / $134.79 $38.42
4. Universal Health Services, Inc. $145.17 5.68 $8.64 B 0.56% 16.23% 21.02% $246.33 / $140.76 $119.15
5. PACS Group, Inc. $37.01 24.33 $5.93 B 6.76% 26.63% $43.08 / $7.5 $6.05
6. Chemed Corporation $441.59 22.45 $5.83 B 0.56% 27.27% 25.33% $565.66 / $365.21 $71.43
7. Option Care Health, Inc. $20.51 15.62 $3.22 B 12.87% 15.28% $36.8 / $18.01 $8.46

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales1.54 B1.48 B1.46 B1.46 B1.41 B
Operating Profit283.4 M243.6 M259.1 M267 M232.3 M
Net Profit146.1 M126.5 M142.1 M151.5 M120.9 M
EPS in Rs1.471.271.431.521.22

Profit & Loss

Figures shown in M / B

2025202420232022
Sales5.94 B5.37 B4.8 B4.35 B
Operating Profit1.05 B864.5 M731.8 M630.2 M
Net Profit566.2 M455.7 M352 M271 M
EPS in Rs5.74.583.542.73

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets7.09 B6.53 B6.1 B5.64 B
Total Liabilities3.81 B3.69 B3.81 B3.77 B
Equity2.44 B2.07 B1.65 B1.31 B
Current Assets905.9 M886.9 M841.8 M717.2 M
Current Liabilities836.4 M841 M656.4 M575.9 M

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF1.18 B1 B850.8 M705.8 M
Investing CF-764.6 M-653.3 M-602.8 M-627 M
Financing CF-431.2 M-330.6 M-197.2 M-145.7 M
Free CF439.2 M360.3 M267.7 M121.7 M
Capex-736.4 M-642.5 M-583.1 M-584.1 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %11.91%10.41%
Earnings Growth %29.46%29.89%
Profit Margin %8.48%7.33%6.23%
Operating Margin %16.09%15.24%14.49%
Gross Margin %41.56%41.3%40.32%
EBITDA Margin %22.08%21.34%20.01%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

Ex DateDividend
2026-04-01$0.19
2026-01-02$0.19
2025-10-01$0.19
2025-07-01$0.17
2025-04-01$0.17
2025-01-02$0.17
2024-10-01$0.17
2024-07-01$0.15
2024-03-28$0.15
2023-12-29$0.15
2023-09-29$0.15
2023-06-30$0.15
2023-03-31$0.15
2022-12-30$0.15
2022-09-30$0.15
2022-07-12$0.28
2022-03-31$0.2228
2021-12-31$0.2228
2021-09-30$0.2228
2021-06-30$0.2228

Stock Splits

DateSplit
2022-07-011:1.257

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
iShares Trust-iShares Core S&P Mid-Cap ETF Mutual Fund 3.22 M $313.75 M 0.03% 2026-01-31
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund Mutual Fund 1.6 M $155.83 M 0.02% 2026-01-31
Blackrock Inc. Institutional 10.31 M $1 B 0.1% 2025-12-31
Vanguard Group Inc Institutional 10.13 M $986.56 M 0.1% 2025-12-31
Invesco Ltd. Institutional 4.97 M $484.29 M 0.05% 2025-12-31
Price (T.Rowe) Associates Inc Institutional 4.81 M $468 M 0.05% 2025-12-31
Wellington Management Group, LLP Institutional 3.38 M $329.65 M 0.03% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund Mutual Fund 3.17 M $308.51 M 0.03% 2025-12-31
State Street Corporation Institutional 3.09 M $300.73 M 0.03% 2025-12-31
T. Rowe Price Investment Management, Inc. Institutional 2.72 M $265.18 M 0.03% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund Mutual Fund 2.28 M $222.37 M 0.02% 2025-12-31
Fuller & Thaler Asset Management Inc. Institutional 2.05 M $200.01 M 0.02% 2025-12-31
Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund Mutual Fund 1.96 M $190.76 M 0.02% 2025-12-31
Geode Capital Management, LLC Institutional 1.95 M $189.53 M 0.02% 2025-12-31
Alliancebernstein L.P. Institutional 1.87 M $181.8 M 0.02% 2025-12-31

Frequently Asked Questions — Encompass Health Corporation

Will Encompass Health Corporation stock hit $125 in 2026?

Encompass Health Corporation (EHC) is currently trading at $104.01, with a 52-week range of $92.77 to $127.99. Reaching the $125 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $142.73 for Encompass Health Corporation, with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $160.0. Whether Encompass Health Corporation can reach $125 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, EHC has delivered a 10.6% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the EHC Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Encompass Health Corporation stock worth buying at $104.01?

Whether Encompass Health Corporation (EHC) is worth buying at $104.01 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Encompass Health Corporation trades at a Price-to-Earnings (P/E) ratio of 16.9x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: Encompass Health Corporation has a Return on Capital Employed (ROCE) of 16.8%, which indicates the business is generating strong returns on the capital it deploys — a hallmark of a high-quality business. Its Return on Equity (ROE) stands at 25.4%, suggesting management is effectively converting shareholder equity into profit.

Financial health: The Debt-to-Equity ratio of 82.85 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for EHC is currently Strong_buy, with a mean price target of $142.73 based on 11 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Encompass Health Corporation (EHC) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $142.73 for Encompass Health Corporation (EHC), aggregated from 11 analyst ratings. The overall analyst recommendation is Strong_buy.

The price target range spans from $130.0 on the bearish end to $160.0 on the most optimistic projection, with a median target of $140.0. This wide range reflects differing views on Encompass Health Corporation's growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the EHC analysis page on StockSifting.

Is Encompass Health Corporation overvalued at a P/E ratio of 16.9x?

Encompass Health Corporation (EHC) currently has a Price-to-Earnings (P/E) ratio of 16.9x, meaning investors are paying $16.9 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 16.9x P/E falls within a moderate range, reflecting reasonable market confidence in Encompass Health Corporation's earnings outlook.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Encompass Health Corporation's ROCE of 16.8% suggests it has moderate capital returns.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of EHC's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

How much can you earn by reinvesting Encompass Health Corporation dividends?

Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of Encompass Health Corporation (EHC). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.

Encompass Health Corporation currently offers a dividend yield of approximately 76.00%. While this may seem modest in isolation, the real power of DRIP emerges over long holding periods. An investor who reinvested dividends consistently over 10–20 years would accumulate significantly more shares than one who took dividends as cash — and those extra shares continue generating their own dividend income.

The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether Encompass Health Corporation grows or cuts its dividend over time. Market price appreciation of EHC also plays a significant role — rising share prices increase the value of your accumulated shares.

Use the EHC DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.